TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT (TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT).
Technetium Tc 99m diphosphonate is a bone-imaging agent that undergoes chemisorption onto hydroxyapatite crystals in bone. Uptake is increased in areas of high bone turnover, such as metastatic lesions, fractures, or inflammation.
| Metabolism | Technetium Tc 99m diphosphonate does not undergo significant metabolism. The diphosphonate ligand may be degraded, but the primary route of elimination is renal excretion of the intact complex. |
| Excretion | Renal: ~100% via glomerular filtration; no biliary/fecal elimination. |
| Half-life | Terminal elimination half-life: 6–8 hours for the diphosphonate complex; clinical context: allows imaging up to 24 hours post-injection. |
| Protein binding | ~50–80% bound to plasma proteins, mainly albumin. |
| Volume of Distribution | 0.5–1.0 L/kg; indicates distribution into total body water with bone uptake. |
| Bioavailability | IV: 100% (only route). |
| Onset of Action | IV: accumulation in bone begins within minutes; optimal imaging at 2–4 hours. |
| Duration of Action | Bone uptake persists for 24–48 hours; imaging window typically 2–24 hours post-injection. |
15-30 mCi (555-1110 MBq) IV single dose for bone scintigraphy.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment guidelines for renal impairment; use caution in severe renal dysfunction due to altered biodistribution. |
| Liver impairment | No adjustment required; not hepatically metabolized. |
| Pediatric use | 0.2-0.3 mCi/kg (7.4-11.1 MBq/kg) IV, minimum dose 1 mCi (37 MBq). |
| Geriatric use | Same as adult dosing; no specific adjustments, but consider renal function and hydration status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT (TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT).
| Breastfeeding | Technetium Tc 99m is excreted into breast milk. M/P ratio not established. Breastfeeding should be interrupted for 24-48 hours after administration to reduce infant radiation exposure. Consider pumping and discarding milk during this period. |
| Teratogenic Risk | Technetium Tc 99m diphosphonate-tin is a radiopharmaceutical. Fetal radiation exposure risks are dose-dependent. In first trimester, risk of teratogenesis is highest; use only if benefit outweighs potential harm. In second and third trimesters, risk of stochastic effects (carcinogenesis) applies. Cumulative fetal dose should be minimized. No specific teratogenic effects reported in humans. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component of the kit"]
| Precautions | ["Risk of allergic reactions including anaphylaxis","Radiation exposure; benefit must outweigh risk","Use in pregnancy only if clearly needed; potential fetal radiation exposure","Lactation: Interrupt breastfeeding for at least 24 hours after administration","Hydration: Ensure adequate patient hydration to reduce radiation dose to bladder","Voiding: Encourage frequent voiding to minimize bladder radiation exposure","False positives: Uptake in benign conditions (e.g., arthritis, recent fracture, infection)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs during injection. No specific fetal monitoring required. Ensure adequate hydration to promote renal clearance of unbound technetium, reducing fetal exposure. Verify pregnancy status before administration. |
| Fertility Effects | No known effects on fertility from diagnostic doses. High radiation doses theoretically could affect gonadal function, but standard imaging doses are below thresholds for reproductive harm. |